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Abstract
Background: Although high grade prostatic intraepithelial neoplasia (HGPIN) is consid-
ered a neoplastic lesion that precedes prostate cancer (PCA), the genomic structures of
HGPIN remain unknown.
Objective: Identiﬁcation of the genomic landscape of HGPIN and the genomic differences
between HGPIN and PCA that may drive the progression to PCA.
Design, settings, and participants: We analyzed 20 regions of paired HGPIN and PCA
from six patients using whole-exome sequencing and array-comparative genomic
hybridization.
Outcome measurements and statistical analysis: Somatic mutation and copy number
alteration (CNA) proﬁles of paired HGPIN and PCA were measured and compared.
Results and limitations: The number of total mutations and CNAs of HGPINs were
signiﬁcantly fewer than those of PCAs. Mutations in FOXA1 and CNAs (1q and 8q gains)
were detected in both HGPIN and PCA (‘common’), suggesting their roles in early PCA
development. Mutations in SPOP, KDM6A, and KMT2Dwere ‘PCA-speciﬁc’, suggesting their
roles in HGPIN progression to PCA. The 8p loss was either ‘common’ or ‘PCA-speciﬁc’. In-
silico estimation of evolutionary ages predicted that HGPIN genomes were much younger
than PCA genomes. Our data show that PCAs are direct descendants of HGPINs in most
cases that require more genomic alterations to progress to PCA. The nature of heteroge-
neous HGPIN population that might attenuate genomic signals should further be studied.
Conclusions: HGPIN genomes harbor relatively fewer mutations and CNAs than PCA but
require additional hits for the progression.
Patient summary: In this study, we suggest a systemic diagram from high grade prostatic
intraepithelial neoplasia (HGPIN) to prostate cancer (PCA). Our results provide a clue to
explain the long latency fromHGPIN to PCA and provide useful information for the genetic
diagnosis of HGPIN and PCA.
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1. Introduction
Prostate cancer (PCA) is the secondmost commonmalignan-
cy in men worldwide, and is responsible for approximately
250,000 cancer-related deaths annually [1]. Prostatic intrae-
pithelial neoplasia (PIN) is defined as a neoplastic growth of
epithelial cells within preexisting prostatic acini or ducts. Of
the PINs, high grade PIN (high grade prostatic intraepithelial
neoplasia [HGPIN], grade 2–3) is considered to be a precursor
for PCA development [2–4]. HGPIN and PCA share many
features such as high rates of occurrence in the peripheral
zone [5–7]. Clinically, more than 40% of HGPIN patients are
diagnosed as PCA within 3 yr of HGPIN diagnosis [3].
Conventional gene-to-gene approaches have found
common genetic alterations of HGPIN and PCA, such as
TMPRSS2-ERG gene fusion and allelic loss of 8p12-21 [8,9],
indicating that HGPIN may be a direct precursor of PCA.
Whole-genome andwhole-exome sequencing (WES) of PCA
[10,11] have found recurrent mutations including SPOP,
MED12, and FOXA1. However, they did not include PIN and
we still do not know the mutational landscape of PIN
genomes. In this study, we hypothesize that HGPIN
progressionmaybemediatedby the acquisitionof additional
somaticmutations and/or copy number alterations (CNAs). A
better way to find genetic differences between HGPIN and
PCA would be to examine them in the same patients. This
approach is, however, challenging because of technical
difficulties in separating HGPIN and PCA lesions.
In this study, to address the hypothesis above, we
analyzed paired HGPIN and PCA using WES and array-
comparative genomic hybridization (array-CGH) using
microdissection and found that HGPIN harbored fewer
mutations and CNAs (especially fewer driver mutations),
suggesting that additional genomic alterations might burst
onto theHGPIN genome or the early PCA genome at the final
stage of progression to PCA.
2. Patients and methods
2.1. Clinical data
Radical prostatectomy tissues from six patients with PCAswere obtained
from the Korea Prostate Bank (Seoul, Korea). All of them were Korean
without known family history of PCA. A total of 20 multiregion biopsies
of HGPIN (n = 10) andmatched primary PCA (n = 10) lesions from the six
patients were used (Table 1) (institutional review board approval at the
Catholic University of Korea). Two PCA samples from each prostate were
taken from the same presumed index focus. Detailed information for
retrieving tissue and genomic analysis is available in the Supplementary
data.
2.2. Genomic analyses
Somatic variants were identiﬁed by comparing sequencing reads of the
tumor and matched normal genomes using Illumina HiSeq2000
platform. Sequences have been deposited to the SRA database (Project
ID: PRJNA293642). Array-CGH was performed using Agilent Sure Print
G3 Human CGH-Microarray 180K [12]. Absolute copy number was
estimated with Sequenza [13] using WES data (Supplementary data).
2.3. Validation of mutations
Mutations identiﬁed with WES were validated by digital-polymerase
chain reaction (PCR), Sanger sequencing, and allele-speciﬁc PCR
(Supplementary data).
2.4. Mutational map
Nonsilent mutations were classiﬁed into three categories of ‘common’,
‘HGPIN-speciﬁc’, and ‘PCA-speciﬁc’. ‘Common’ represents the mutations
identiﬁed in bothHGPIN andmatched PCA and ‘speciﬁc’ represents those
only in HGPIN or PCA. Phylogeny trees were drawn using somatic
alterations with respect to the mutational categories.
3. Results
3.1. Whole-exome sequencing of HGPIN and matched PCA
genomes
A total of 26 multiregion biopsies of HGPINs (n = 10), PCAs
(n = 10) and matched normal-tissues (n = 6) in six patients
were analyzed (Table 1). Coverages of WES were a median
of 196X (quartiles 174X, 246X) for normal, 181X (quartiles
168X, 203X) for HGPINs, and 187X (quartiles 178X, 213X)
for PCAs (Supplementary Table 1). Mutation numbers of the
PCAs were significantly higher than those of the HGPINs
(p < 0.001) (Fig. 1A, Table 2, Supplementary Table 2). PCAs
had significantly higher mutant allele frequencies (MAFs)
Table 1 – Clinicopathologic characteristics of six prostate cancers with high grade intraepithelial neoplasia
Patient (Age, yr) Samples Size of PCA
(diameter, cm)
Gleason score
of PCA
T/N/M
of PCA
PSA
(ng/ml)
TMPRSS2-ERG fusion
status in HGPIN or PCA
HGPIN PCA
PCA3 (60) HGPIN3 PCA3 3.5 3 + 4 3a/0/0 8.48 negative
PCA17 (67) HGPIN17-1 PCA17-1 1.6 3 + 4 2c/0/0 4.66 negative
HGPIN17-2 PCA17-2
PCA25 (62) HGPIN25-1 PCA25-1 4 5 + 3 3b/0/0 11.01 negative
HGPIN25-2 PCA25-2
PCA43 (67) HGPIN43 PCA43 1.8 3 + 4 2c/0/0 9.53 negative
PCA78 (69) HGPIN78-1 PCA78-1 1.5 3 + 4 2c/0/0 4.89 negative
HGPIN78-2 PCA78-2
PCA89 (74) HGPIN89-1 PCA89-1 2.3 3 + 3 3a/0/0 12.27 negative
HGPIN89-2 PCA89-2
HGPIN = high grade prostatic intraepithelial neoplasia; PCA = prostate cancer; T/N/M = tumor/lymph node/metastasis; PSA = prostate speciﬁc antigen.
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than HGPINs (p < 0.001, Fig. 1B, Table 2). Based on these
MAFs, we estimated the evolutionary ages of HGPIN and
PCA genomes in the six cases by an evolutionary model
[14]. The number of clonal mutations in HGPIN genomes
was 0 to 17 (a conservative estimate of the evolutionary age
of 0 to 680 cell cycles). For PCA, it was 16 to 48 clonal
mutations corresponding to 640 to 1,920 cell cycles. The
evolutionary ages of PCAs were significantly longer than
those of HGPINs (p < 0.001, Table 2, Supplementary Fig. 1).
3.2. Cancer-related genes
To address whether the mutations found in our study were
causally implicated in HGPIN progression to PCA, we
queried cancer-related genes from the cancer Gene Census
[15] and key PCA genome studies [10,11]. Eight cancer-
related genes were identified in either the cancer Gene
Census or the PCA genome studies: FOXA1, SPOP, KDM6A,
KMT2D, APC, HRAS, CYLD, and MLLT4 (Fig. 2). Previously
known hotspot mutations such as SPOP (p.W131C), FOXA1
(p.M253K), andHRAS (p.Q61K) were recurrently detected in
this study (Supplementary Table 3). FOXA1 (p.M253K)
mutation was identified as ‘common’, while SPOP, KDM6A,
KMT2D, MLLT4, and APC mutations as ‘PCA-specific’ (Fig. 2,
Supplementary Fig. 2). HRAS (p.Q61K) and FOXA1 (p.R219S)
mutations were identified as ‘HGPIN-specific’. We validated
18mutations either with digital-PCR, mutant allele-specific
PCR, or Sanger sequencing (Supplementary Table 4, Sup-
plementary Fig. 3). MAF profiles were not significantly
different between WES and digital-PCR (p = 0.676).
3.3. CNAs
A total of 279 CNAs were identified in the 10 HGPINs and
10 PCAs (Fig. 1C, Supplementary Fig. 4, Supplementary
Table 5). The PCAs harbored significantly higher numbers of
(p < 0.001) and longer CNAs (p = 0.003) than the HGPINs
(Table 2). A copy loss on 8p21.3-p11.21, a copy gain on
[(Fig._1)TD$FIG]
Fig. 1 – Abundance of somatic mutations and copy number alteration profiles in 10 high grade prostatic intraepithelial neoplasia (HGPIN) and
10 prostate cancer (PCA) genomes. (A) The numbers of somatic mutations are shown with the five functional categories. (B) Mutant allele frequencies
(y-axis) of point mutations are shown for HGPIN and PCA genomes. There is a significant difference between them (p < 0.001). (C) The numbers of copy
number alterations identified in each HGPIN and PCA genome.
[4_TD$DIFF]CNA = copy number alterations; HGPIN = high grade prostatic intraepithelial neoplasia; PCA = prostate cancer.
* Represents outliers.
Table 2 – Summary of comparison data between high grade intraepithelial neoplasia and prostate cancer genomes
HGPIN, median (quartiles) PCA, median (quartiles) p value
Somatic mutation number 5.5 (2.3, 14) 34.5 (28, 39) <0.001
Mutation allele frequency 0.06 (0.044, 0.089) 0.19 (0.071, 0.28) <0.001
Mutation allele frequency (nonsilent) 0.06 (0.044, 0.084) 0.19 (0.071, 0.27) <0.001
Mutation allele frequency (silent) 0.06 (0.045, 0.13) 0.21 (0.072, 0.30) <0.001
Inferred evolutionary age (cycles) 180 (50, 490) 1220 (1000, 1390) <0.001
No. of CNAs 1 (0, 2) 17.5 (8.5, 25) <0.001
Length of CNAs (Mbp) 0.34 (0, 1.8) 66.9 (35, 261) 0.003
CNAs = copy number alterations; HGPIN = high grade prostatic intraepithelial neoplasia; PCA = prostate cancer.
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1q21.2-q44 harboring ARNT gene, and another gain on
8q11.1-q24.3 harboring MYC were identified in both
HGPIN3 and PCA3 (Supplementary Fig. 5). Of the 279 CNAs,
two gains and 22 losses were identified recurrently (2
cases) (Supplementary Table 6). The PCA genomes harbored
significantly higher numbers of recurrent CNAs (p = 0.013).
The most recurrent CNA was 8p23.3-p11.1 deletion, where
a PCA suppressor,NKX3-1, is located (Fig. 3). The 8p loss was
identified in one (HGPIN3) of the six HGPINs (16.7%)while it
was identified in all six PCAs (100%) (Supplementary Fig. 6).
There is a significant difference in 8p loss between PCAs and
HGPINs (p = 0.015). Well-known oncogenes (7p22.3-p14.1
[ETV1] gain) and tumor suppressor genes (6q14.2-q22.33
[MAP3K7 and FOXO3] and 13q12.2-q21.1 [RB1] losses) were
also located in the recurrent regions. Two candidate
chromothripses were observed on chromosome 7q in two
PCAs. They were PCA-specific (PCA17-1 and PCA78-1)
(Fig. 4A).
3.4. Mutations co-occurred with CNAs
We detected 16 mutations that co-occurred with CNAs in
the same patients (Supplementary Table 7). APC mutation
co-occurred with 5q22.2 deletion in PCA17-1 and PROSER1
mutation co-occurred with 13q13.3 deletion in PCA78-2
(Fig. 4B).
3.5. Mutational map of prostate carcinogenesis
In the phylogeny trees, cancer-related genes are shown
together with CNAs in the trunk (‘common’) and branches
(‘HGPIN-specific’ or ‘PCA-specific’) (Fig. 5). Of note, CNAs on
[(Fig._2)TD$FIG]
Fig. 2 – Schematics of regional distribution of somatic mutations in high grade prostatic intraepithelial neoplasia (HGPIN) and prostate cancer (PCA).
Mutations in each patient are shown with respect to three mutational categories (‘common’, ‘HGPIN-specific’, and ‘PCA-specific’) and regional
distribution in six PCAs with matched HGPINs (PCA3, PCA17, PCA25, PCA43, PCA78, and PCA89). The mutation calls for HGPIN (gray) and PCA (black)
lesions are shown as bar plot. Names of cancer-related genes with nonsilent mutations are indicated.
HGPIN = high grade prostatic intraepithelial neoplasia; PCA = prostate cancer.
*: number of genes with nonsilent mutations.
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8p23.3-p11.21 were located on either the trunk or ‘PCA-
specific’ branches. At least one or more mutations (variant
level) and CNAs are overlapped in both HGPIN and cancer of
the same prostates (PCA3, PCA17, PCA43, and PCA78).
However, in PCA25 and PCA89 cases, any HGPIN mutations
are not overlapped with those in cancers of the same
prostates (Fig. 5, Supplementary Fig. 7).
4. Discussion
In this study, we attempted to identify somatic mutations
and CNAs of HGPIN, and to identify genomic differences
between HGPIN and PCA that may drive the progression to
PCA. HGPINs harbored somatic mutations including driver
mutations (FOXA1 andHRAS) and CNAs, but theywere fewer
than those in PCAs. These data suggest that HGPIN is a true
neoplastic lesion with genetic alterations, but has quanti-
tatively and qualitatively naive genomes, that may require
additional genetic events to develop PCA. To obtain reliable
mutation calling, we not only performed WES with decent
read depths, but also validated the low MAF mutations
using digital-PCR. Although many of the cancer-related
gene mutations in HGPINs exhibited low MAFs, they were
successfully confirmed using digital-PCR (Supplementary
Table 4). Together, these data may provide evidence of
cancer-related mutations in the early stage of prostate
tumorigenesis that have not been detected in previous
studies.
[(Fig._3)TD$FIG]
Fig. 3 – Deletion on 8p23.3-p11.1 encompassing NKX3-1 gene. The most common copy number alteration detected is the deletion on 8p23.3-p11.1,
where the tumor suppressor gene, NKX3-1, is located. Copy number profiles on the chromosome 8 in the six prostate cancer samples with matched
high grade prostatic intraepithelial neoplasias are shown in the left panel. Red color denotes the copy number gains and blue color denotes the copy
number losses. Detailed signal intensity plots of the copy number alterations on chromosome 8 in the six PCAs are shown in right panel. The x-axis
represents the genomic location and the y-axis represents signal intensities on the log2 scale.
HGPIN = high grade prostatic intraepithelial neoplasia; PCA = prostate cancer.
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‘Common’ alterations such as FOXA1 mutation in PCA78
and CNAs on 1q, 3p, 3q, 8p, 8q, and 13q in PCA3were found,
but neither of them was recurrent in the other HGPINs,
suggesting that there may be [11_TD$DIFF]neither a single driver [12_TD$DIFF]nor a
group of cancer-related genes for the initiation of prostate
tumorigenesis, but that nonrecurrent alterations may
cooperate together. Acquisition of driver events may have
occurred at a late stage of HGPIN so that few driver
mutations would be found in HGPINs. Six cancer-related
genes including SPOP, KDM6A, KMT2D, and APC, were ‘PCA-
specific’. They may not be involved in the early initiation
step (HGPIN), but acquired at the final stage of HGPIN or
after HGPIN progression to PCA and may play a role in
HGPIN progression to PCA. HRAS p.Q61K was detected in
HGPIN25-1, but not in the others (HGPIN25-2, PCA25-1, and
PCA25-2). FOXA1 p.R219S was detected in HGPIN78-1, but
not in the others (HGPIN78-2, PCA78-1, and PCA78-2).HRAS
p.Q61K is detected in many cancers including thyroid,
prostate, and bladder cancers [16–19]. To our knowledge,
this is the first report on HRAS p.Q61K mutation in HGPINs.
An explanation for the HGPIN-specificity is based on the
‘field effect’, uponwhich further environmental exposure to
carcinogens could lead to the formation ofmultiple prostate
precursors [20]. There might be a HGPIN with FOXA1 or
HRASmutation that was not related to the PCA in a prostate.
It is uncertain that the HGPIN with ‘HGPIN-specific’
mutations is a ‘dead end’ lesion that does not progress to
PCA since another area besides the PCAs analyzed could
possibly harbor thesemutations. Possibly, it would progress
to a PCA if untreated.
[(Fig._4)TD$FIG]
Fig. 4 – Copy number profiles for chromothripsis and for co-occurrence of copy number alterations with mutations. (A) The complex recombination
events (chromothripses) were observed on chromosome 7 in PCA17-1 and PCA78-1. There is no evidence of chromosome 7 chromothripsis in any
other regional biopsies of these two cases. The x-axis represents the genomic location and the y-axis represents signal intensities on log2 scale.
(B) Co-occurrence of APC mutation with a deletion on 5q22.2 (upper) and PROSER1 mutation with a deletion on 13q13.3 (lower) are shown. The x-axis
represents the genomic location and the y-axis represents signal intensities on log2 scale.
HGPIN = high grade prostatic intraepithelial neoplasia; PCA = prostate cancer.
Fig. 5 – Phylogeny trees of somatic alterations for the prostate carcinogenesis. For each case (PCA3, PCA17, PCA25, PCA43, PCA78, and PCA89),
phylogenetic trees were constructed using both nonsilent mutations and copy number alterations with respect to the three mutation categories. The
length of the branches was estimated from the mutational abundance in the corresponding branches.
HGPIN = high grade prostatic intraepithelial neoplasia; PCA = prostate cancer.
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Regional profiles of themutations (Supplementary Fig. 2)
exhibited that not all of them were present in two cancer
samples of the same prostate, although they were taken
from the same presumed index focus, suggesting existence
of intratumoral heterogeneity (ITH) or ‘collisions’ of
genetically distinct PCAs. PCA is frequently multifocal
[20], whichmay complicate experimental studies especially
those usingmultiple tissue-sampling like this study. Even in
the same index focus, ‘collisions’ of genetically distinct PCAs
may frequently result in discordant genetic data [21]. Also,
unifocal PCAs harbor ITH of somatic mutation profiles
[12]. Practically, passenger mutations at variant levels are
not usually recurrent in two different tumors while driver
mutations can be recurrent in two different tumors
[22,23]. Thus, recurrent passenger mutations including
silent mutations in regional biopsies within a prostate
suggest uniclonal PCAs from a same ancestor (ITH). In our
data, two regional cancer biopsies of PCA25 and PCA89 (25-
1 and 25-2; 89-1 and 89-2) have overlapped passenger
mutations supporting ITH. By contrast, two regions of
PCA17 (17-1 and 17-2) and PCA78 (78-1 and 78-2) have no
overlapped passenger mutations, thus suggesting ‘colli-
sions’ (Supplementary Fig. 7).
In this study, we analyzed the CNAs using both array-
CGH and WES, and identified a fairly good concordance
between them (80%) supporting a reliability of the CNA
profiles in this study (Supplementary data). Gains on
1q21.2-q44 harboring ARNT and on 8q11.1-q24.3 harboring
MYC were identified as ‘common’ in a case (PCA3). In
agreement with these, gains on 8q have been observed in
both HGPIN and PCA [2,8] and amplification of ARNT has
been observed in PCA previously [24]. Deletion on 8p23.3-
p11.1 encompassing NKX3-1 was detected in both HGPIN
and PCA in a case (PCA3) and in PCA alone in the other five
cases (PCAs 17, 25, 43, 78, and 89). Loss of NKX3-1
expression was reported to be common in both PCA and
PIN lesions and to correlate with tumor progression
[25]. Emmert-Buck et al. [26] observed loss of heterozygos-
ity on 8p12-21 in 63% of HGPINs and 90.6% of PCAs
[26]. Together, our data and the previous data indicate that
8p loss in the prostate plays a role in both development and
progression of PCA. Signal intensities of the CNAs identified
in HGPINs, however, were relatively lower than PCAs
(Supplementary Fig. 4), which might come from low purity
of HGPIN. For this, we estimated the purity using prediction
tools (Supplementary data). PCA genomeswere predicted to
have similar (50–78%) purity with the histologically
estimated purity. However, for HGPIN, purity was incalcu-
lable by two algorithms, while it was predicted very low
(23–37%) by another algorithm, possibly suggesting that
HGPIN purity might be lower than histologically predicted.
Although, based on the microdissection, it seemed that
there would be little chance for normal or PCA cell
contamination in HGPINs (Supplementary Fig. 8). Being
histologically defined, the HGPIN cells might have geneti-
cally heterogeneous or polyclonal components that would
attenuate the signals. This could be verified by doing 8p
fluorescence in-situ hybridization in the areas of HGPIN to
look for heterogeneity of copy loss in future studies.
In PCA3, PCA17, PCA[2_TD$DIFF]43, and PCA78 cases, HGPINs and
cancers in the same prostates shared genetic alterations,
supporting the dogma that prostate cancer is a descendant of
HGPIN. However, in PCA[2_TD$DIFF] 5 and PCA89 cases, no overlapped
alterations between HGPINs and cancers were observed.
There may be two possibilities for these cases that should be
further studied in future studies. Firstly, HGPINs do not
precede PCAs in some cases. Secondly, there are hidden or
unbiopsied HGPINs that are related to PCAs in such cases.
Chromothripsis has been observed across many cancers
including PCA, but not in PIN [9]. A prevailing view supports
early occurrences of chromothripsis in cancer evolution
[27,28], but ‘how early’ is undefined. In our study, we found
chromothripses in PCAs, but not in HGPINs, suggesting that
HGPIN may be genetically too young to harbor chromo-
thripsis. Even in the era of next generation sequencing, we
still do not understand the genomes of premalignant lesions
of cancers such as HGPIN. For a better understanding, we
used a microdissection of HGPIN from frozen sections,
which provided enough quality and quantity of genomic
DNA for both WES and array-CGH.
5. Conclusions
This study identified not only mutational landscapes of
HGPIN for the first time, but also found the existence of
cancer-related gene mutations in HGPINs. We also identi-
fied that HGPIN genomes were less aggressive than PCA
genomes in both quantity and quality. PCA genomes were
found to be direct descendants of HGPIN genomes that
require more changes to progress to PCA. Although our
study first described genome-level alterations, it has several
technical limitations that should be further validated in
future studies, for example, identification, isolation, and
analysis of heterogeneous HGPINs. Single-cell or single-
gland level analysis of HGPIN and PCA is required to further
disclose clonal and evolutionary structure of HGPIN and
PCA. In summary, we suggest a systemic diagram from
HGPIN to PCA. The first step is genomic changes during
HGPIN development such as somatic mutations (eg, HRAS
and FOXA1) and CNAs (eg, gains of 1q and 8q). The next step
is the addition of cancer-related alterations such as SPOP,
KDM6A, and KMT2Dmutations to develop PCA. 8p loss may
be involved in both the development and progression of
HGPIN. Discernable genomic features of HGPIN from PCA
identified in this study provides a useful resource for
understanding this common and latently progressing
disease (HGPIN) and for dissecting genomic clues for
clinical decision-making in the differential diagnosis and
therapy options for HGPIN and PCA.
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